Raymond B King1,2, Sarah Os Osman1,2, Ciaran Fairmichael1,3, Denise M Irvine2, Ciara A Lyons1,3,4, Ananth Ravi5, Joe M O'Sullivan1,3, Alan R Hounsell1,2, Darren M Mitchell3, Conor K McGarry1,2, Suneil Jain1,3. 1. 1 Centre for Cancer Research and Cell Biology, Queen's University Belfast , Belfast , Ireland. 2. 2 Radiotherapy Physics, Northern Ireland Cancer Centre, Belfast City Hospital , Belfast , Ireland. 3. 3 Department of Clinical Oncology, Northern Ireland Cancer Centre, Belfast City Hospital , Belfast , Ireland. 4. 4 Department of Clinical Oncology, North West Cancer Centre, Altnagelvin Area Hospital , Londonderry , Northern Ireland. 5. 5 Department of Medical Physics, Odette Cancer Centre, Sunnybrook Health Sciences Centre , Toronto , Canada.
Abstract
OBJECTIVE: This study assessed the use of implanted hydrogel rectal spacers for stereotactic ablative radiotherapy-volumetric modulated arc therapy (SABR-VMAT) patients, investigating practicality, dosimetric impact, normal tissue complication probability (NTCP) and early toxicity. METHODS: Data from the first 6 patients treated within a prostate SABR and rectal spacer trial were examined to determine spacer insertion tolerability, resultant changes in treatment planning and dosimetry and early toxicity effects. CT scans acquired prior to spacer insertion were used to generate SABR plans which were compared to post-insertion plans. Plans were evaluated for target coverage, conformity, and organs at risk doses with NTCPs also determined from resultant dose fluences. Early toxicity data were also collected. RESULTS: All patients had successful spacer insertion under local anaesthetic with maximal Grade 1 toxicity. All plans were highly conformal, with no significant differences in clinical target volume dose coverage between pre- and post-spacer plans. Substantial improvements in rectal dose metrics were observed in post-spacer plans, e.g. rectal volume receiving 36 Gy reduced by ≥42% for all patients. Median NTCP for Grade 2 + rectal bleeding significantly decreased from 4.9 to 0.8% with the use of a rectal spacer (p = 0.031). To date, two episodes of acute Grade 1 proctitis have been reported following treatment. CONCLUSION: The spacer resulted in clinically and statistically significant reduction in rectal doses for all patients. Advances in knowledge: This is one of the first studies to investigate the efficacy of a hydrogel spacer in prostate SABR treatments. Observed dose sparing of the rectum is predicted to result in meaningful clinical benefit.
OBJECTIVE: This study assessed the use of implanted hydrogel rectal spacers for stereotactic ablative radiotherapy-volumetric modulated arc therapy (SABR-VMAT) patients, investigating practicality, dosimetric impact, normal tissue complication probability (NTCP) and early toxicity. METHODS: Data from the first 6 patients treated within a prostate SABR and rectal spacer trial were examined to determine spacer insertion tolerability, resultant changes in treatment planning and dosimetry and early toxicity effects. CT scans acquired prior to spacer insertion were used to generate SABR plans which were compared to post-insertion plans. Plans were evaluated for target coverage, conformity, and organs at risk doses with NTCPs also determined from resultant dose fluences. Early toxicity data were also collected. RESULTS: All patients had successful spacer insertion under local anaesthetic with maximal Grade 1 toxicity. All plans were highly conformal, with no significant differences in clinical target volume dose coverage between pre- and post-spacer plans. Substantial improvements in rectal dose metrics were observed in post-spacer plans, e.g. rectal volume receiving 36 Gy reduced by ≥42% for all patients. Median NTCP for Grade 2 + rectal bleeding significantly decreased from 4.9 to 0.8% with the use of a rectal spacer (p = 0.031). To date, two episodes of acute Grade 1 proctitis have been reported following treatment. CONCLUSION: The spacer resulted in clinically and statistically significant reduction in rectal doses for all patients. Advances in knowledge: This is one of the first studies to investigate the efficacy of a hydrogel spacer in prostate SABR treatments. Observed dose sparing of the rectum is predicted to result in meaningful clinical benefit.
Authors: Michael Pinkawa; Nuria Escobar Corral; Mariana Caffaro; Marc D Piroth; Richard Holy; Victoria Djukic; Gundula Otto; Felix Schoth; Michael J Eble Journal: Radiother Oncol Date: 2011-09-29 Impact factor: 6.280
Authors: Danny Y Song; Klaus K Herfarth; Matthias Uhl; Michael J Eble; Michael Pinkawa; Baukelien van Triest; Robin Kalisvaart; Damien C Weber; Raymond Miralbell; Theodore L Deweese; Eric C Ford Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-13 Impact factor: 7.038
Authors: Neil Mariados; John Sylvester; Dhiren Shah; Lawrence Karsh; Richard Hudes; David Beyer; Steven Kurtzman; Jeffrey Bogart; R Alex Hsi; Michael Kos; Rodney Ellis; Mark Logsdon; Shawn Zimberg; Kevin Forsythe; Hong Zhang; Edward Soffen; Patrick Francke; Constantine Mantz; Peter Rossi; Theodore DeWeese; Daniel A Hamstra; Walter Bosch; Hiram Gay; Jeff Michalski Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-23 Impact factor: 7.038
Authors: Andrew Loblaw; Patrick Cheung; Laura D'Alimonte; Andrea Deabreu; Alexandre Mamedov; Liying Zhang; Colin Tang; Harvey Quon; Suneil Jain; Geordi Pang; Robert Nam Journal: Radiother Oncol Date: 2013-05-03 Impact factor: 6.280
Authors: Sarah O S Osman; Emily Russell; Raymond B King; Karen Crowther; Suneil Jain; Cormac McGrath; Alan R Hounsell; Kevin M Prise; Conor K McGarry Journal: Radiat Oncol Date: 2019-12-26 Impact factor: 3.481
Authors: Sarah O S Osman; Ciaran Fairmichael; Glenn Whitten; Gavin S Lundy; Rachel Wesselman; Melissa LaBonte Wilson; Alan R Hounsell; Kevin M Prise; Denise Irvine; Conor K McGarry; Suneil Jain Journal: Radiat Oncol Date: 2022-02-22 Impact factor: 3.481
Authors: Heather A Payne; Michael Pinkawa; Clive Peedell; Samir K Bhattacharyya; Emily Woodward; Larry E Miller Journal: Medicine (Baltimore) Date: 2021-12-10 Impact factor: 1.817